Personalized PRRT of Neuroendocrine Tumors

In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs. The purpose of this study is to: * Assess the objective (radiological), symptomatic and biochemical response rates following an induction course of personalized PRRT; * Assess the overall, the disease-specific, and the progression-free survival following P-PRRT; * Correlate therapeutic response and survival with tumor absorbed radiation dose; * Evaluate the acute, subacute and chronic adverse events following P-PRRT; * Correlate toxicity (i.e. occurence and severity of adverse events) with absorbed radiation doses to organs at risk; * Optimize the quantitative SPECT imaging-based dosimetry methods in a subset of 20 patients (sub-study funded by the Canadian Institutes of Health Research). This study also has a compassionate purpose, which is to provide access to PRRT to patients.

NCT Number	NCT02754297
Lead Sponsor	CHU de Quebec-Universite Laval
Conditions	Neuroendocrine Tumors, Carcinoid Tumor, Carcinoma, Neuroendocrine
Enrollment	275 participants
Start Date	2016-04-12
Primary Completion	2025-04-12 (estimated)
Study Completion	2029-04-12 (estimated)
Updated on ClinicalTrials.gov	2024-08-21